Literature DB >> 21986841

Inhibition of Myb-dependent gene expression by the sesquiterpene lactone mexicanin-I.

T Bujnicki1, C Wilczek, C Schomburg, F Feldmann, P Schlenke, C Müller-Tidow, T J Schmidt, K-H Klempnauer.   

Abstract

The c-myb proto-oncogene encodes a transcription factor that is highly expressed in the progenitor cells of the hematopoietic system, where it regulates the expression of genes important for lineage determination, cell proliferation and differentiation. There is strong evidence that deregulation of c-myb expression is involved in the development of human tumors, particularly of certain types of leukemia, and breast and colon cancer. The c-Myb protein is therefore an interesting therapeutic target. Here, we have investigated the potential of natural sesquiterpene lactones (STLs), a class of compounds that are active constituents of a variety of medicinal plants, to suppress Myb-dependent gene expression. We have developed a test system that allows screening of compounds for their ability to interfere with the activation of Myb target genes. Using this assay system, we have identified the STL mexicanin-I as the first cell-permeable, low-molecular-weight inhibitor of Myb-induced gene expression.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21986841     DOI: 10.1038/leu.2011.275

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  16 in total

1.  An isoform-specific C/EBPβ inhibitor targets acute myeloid leukemia cells.

Authors:  A Jakobs; S Uttarkar; C Schomburg; S Steinmann; A Coulibaly; P Schlenke; W E Berdel; C Müller-Tidow; T J Schmidt; K-H Klempnauer
Journal:  Leukemia       Date:  2016-02-08       Impact factor: 11.528

Review 2.  Transcription Factor Inhibition: Lessons Learned and Emerging Targets.

Authors:  Andrew Chen; Angela N Koehler
Journal:  Trends Mol Med       Date:  2020-02-15       Impact factor: 11.951

3.  The Myb-p300 Interaction Is a Novel Molecular Pharmacologic Target.

Authors:  Xi Liu; Kathryn A Gold; Ethan Dmitrovsky
Journal:  Mol Cancer Ther       Date:  2015-05-20       Impact factor: 6.261

Review 4.  Therapeutic targeting of oncogenic transcription factors by natural products in eye cancer.

Authors:  Michelle G Zhang; John Y Lee; Ryan A Gallo; Wensi Tao; David Tse; Ravi Doddapaneni; Daniel Pelaez
Journal:  Pharmacol Res       Date:  2017-12-02       Impact factor: 7.658

5.  Targeting CDK6 and BCL2 Exploits the "MYB Addiction" of Ph+ Acute Lymphoblastic Leukemia.

Authors:  Marco De Dominici; Patrizia Porazzi; Angela Rachele Soliera; Samanta A Mariani; Sankar Addya; Paolo Fortina; Luke F Peterson; Orietta Spinelli; Alessandro Rambaldi; Giovanni Martinelli; Anna Ferrari; Ilaria Iacobucci; Bruno Calabretta
Journal:  Cancer Res       Date:  2017-12-12       Impact factor: 12.701

6.  New strategies in pediatric gliomas: molecular advances in pediatric low-grade gliomas as a model.

Authors:  Eric Raabe; Mark W Kieran; Kenneth J Cohen
Journal:  Clin Cancer Res       Date:  2013-07-23       Impact factor: 12.531

Review 7.  Natural Products with Antitumor Potential Targeting the MYB-C/EBPβ-p300 Transcription Module.

Authors:  Thomas J Schmidt; Karl-Heinz Klempnauer
Journal:  Molecules       Date:  2022-03-23       Impact factor: 4.411

8.  Kruppel-like factor KLF4 facilitates cutaneous wound healing by promoting fibrocyte generation from myeloid-derived suppressor cells.

Authors:  Lingling Ou; Ying Shi; Wenqi Dong; Chunming Liu; Thomas J Schmidt; Prakash Nagarkatti; Mitzi Nagarkatti; Daping Fan; Walden Ai
Journal:  J Invest Dermatol       Date:  2015-01-12       Impact factor: 8.551

9.  C/EBPβ is a MYB- and p300-cooperating pro-leukemogenic factor and promising drug target in acute myeloid leukemia.

Authors:  Maria V Yusenko; Amke Trentmann; Debora A Casolari; Luca Abdel Ghani; Mairin Lenz; Melanie Horn; Wolfgang Dörner; Stefan Klempnauer; Henning D Mootz; Maria Francisca Arteaga; Jan-Henrik Mikesch; Richard J D'Andrea; Thomas J Gonda; Carsten Müller-Tidow; Thomas J Schmidt; Karl-Heinz Klempnauer
Journal:  Oncogene       Date:  2021-05-06       Impact factor: 9.867

10.  The natural anti-tumor compound Celastrol targets a Myb-C/EBPβ-p300 transcriptional module implicated in myeloid gene expression.

Authors:  Anna Coulibaly; Astrid Haas; Simone Steinmann; Anke Jakobs; Thomas J Schmidt; Karl-Heinz Klempnauer
Journal:  PLoS One       Date:  2018-02-02       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.